Navigation Links
Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/12/2011

NEW YORK, Dec. 12, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that Ivan Bergstein, MD, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 10:15 a.m. ET at the Waldorf Astoria Hotel in New York City.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
4. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
5. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
6. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. Announces Reverse Stock Split
8. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
10. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Wilmington, DE (PRWEB) June 18, 2013 ... teachers to the 11th annual DuPont National AgriScience Teachers ... Chesapeake Farms in Chestertown, Md. , ... sponsored by DuPont and is a special project of ... National Association of Agricultural Educators (NAAE) . The ...
(Date:6/18/2013)... 2013 Edison Investment ... announces the initiation of full coverage of ... developing and marketing products for orphan oncology ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has ... investment merits of BioAlliance Pharma, focusing in ...
(Date:6/18/2013)... 18, 2013 This webinar will ... advertising and promotion, and review the basic FDA ... how to apply these principles through real world ... ,     The fundamentals on FDA regulations and guidance ... ,     Assessing traditional and newer forms of ...
(Date:6/18/2013)... June 18, 2013 ... ) has announced the addition of ... & Stable Isotopes Market [SPECT/PET Radioisotopes ... Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, ... report to their offering. ...
Breaking Biology Technology:DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3
... Newly published data by Dr. J.,Barthelow Classen shows ... children with a strong family history of insulin ... diabetes in,vaccine recipients at a rate which exceeds ... vaccines are particularly toxic to those,with a strong ...
... and COLUMBIA, S.C., Feb. 24 ,CareEvolution, Inc. ... & Statistics,are pleased to announce that the ... named a finalist in the Interoperability category ... (MS-HUG) 2008 Innovation,Awards Program. The MS-HUG Healthcare ...
... Feb. 22 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, ... Conference Call, ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the ...
Cached Biology Technology:CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 2CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 3
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... India reduce rates of syphilis, HIV and other sexually ... found. , About two million Indians are ... Andhra Pradesh, Karnataka, Maharashtra and Tamil Nadu. The study, ... Dalla Lana School of Public Health and St. Michael,s ... impact of prevention among female sex workers whose contact ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... Ph.D., Assistant Adjunct Professor, Department of Medicine, University of ... Society for Microbiology (ASM) to receive a 2010 ICAAC ... Division, this award recognizes an early career scientist for ... Diep earned his B.A. in 2000 and his Ph.D. ...
... the "deathstalker" scorpion could help gene therapy become an effective ... therapeutic genes genes that treat disease to reach ... study in ACS Nano , a monthly journal. ... delivery of therapeutic genes into diseased cells shows promise ...
... a substance to enhance the visibility of skin cancer cells ... ultrasound and light. The hybrid scanner could enable doctors to ... its earliest and most curable stages, the report in the ... Younan Xia, and colleagues point out that early diagnosis is ...
Cached Biology News:
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
... Signets FAST RED Chromogen System consists of ... RED reacts in the presence of alkaline ... background noise. The FAST RED System ... ,The System Contains: , , Vial A: ...
The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
... effectively in tubes and 96 well plates. microCLEAN ... one and a half spin DNA cleanup reagent. ... concentrate any type of double stranded DNA, efficiently ... dNTPs (labelled or unlabelled). It is therefore ideally ...
Biology Products: